Actively Recruiting
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
Led by University Hospital Schleswig-Holstein · Updated on 2025-09-22
2000
Participants Needed
1
Research Sites
339 weeks
Total Duration
On this page
Sponsors
U
University Hospital Schleswig-Holstein
Lead Sponsor
U
UCB Biopharma SRL
Collaborating Sponsor
AI-Summary
What this Trial Is About
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
CONDITIONS
Official Title
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 50 and 99 years
You will not qualify if you...
- Presence of clinical Parkinson's Disease at the time of study inclusion
- Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
- Other significant diseases such as orthopedic diseases affecting quantitative motor assessment
- For participants in the lumbar puncture substudy: contraindications for lumbar puncture such as bleeding tendency or use of anticoagulants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department for Neurology, University of Kiel
Kiel, Germany, 24118
Actively Recruiting
Research Team
E
Eva Schaeffer, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here